OBJECTIVE: Study of the impact of the monitoring mode on the duration of the latency period and on the latency ratio after PPROM, and analysis of the risk factors modifying this ratio.
METHODS: This was a bicentric retrospective cohort study here-abouts including patients who presented a PPROM between 24 and 36weeks of gestation from 2016 to 2018. Patients had a follow-up in HC at Lille University Hospital center (UHC) and in CH at Nantes UHC according to two different follow-up protocols. The latency ratio corresponded to the real latency period divided by the latency period to theoretical term.
RESULTS: We included 154 patients: 102 in HC and 52 in CH. The mean latency period was significantly higher in HC: 36.9±21.8 days, corresponding to an 85.5±23.7% latency ratio versus 20.2±12 days, corresponding to an 66.9±29.8% latency ratio in CH (P<0.001). The latency ratio in CH was correlated with term at PPROM (P=0.001).
CONCLUSIONS: The duration of the latency period seems prolonged for PPROM followed by HC management versus CH in selected populations. This study suggests a benefit to HC in stable patients.
目的:研究监测模式对潜伏期持续时间和PPROM后潜伏期比率的影响,并分析修改这一比率的风险因素。
方法:这是一项双中心回顾性队列研究,包括2016年至2018年妊娠24至36周出现PPROM的患者。根据两种不同的随访方案,患者在里尔大学医院中心(UHC)的HC和南特UHC的CH中进行了随访。延迟比对应于实际延迟周期除以理论项的延迟周期。
结果:我们纳入了154例患者:102例HC和52例CH。HC的平均潜伏期明显较高:36.9±21.8天,对应于85.5±23.7%的延迟率与20.2±12天,对应于CH的66.9±29.8%的延迟率(p<0.001)。CH的潜伏期比率与PPROM时的足月相关(p=0.001)。
结论:在选定人群中,PPROM和HC管理的潜伏期持续时间似乎延长,而不是CH。这项研究表明,对稳定患者的HC有益。